MZT2A: A Potential Drug Target and Biomarker (G653784)

Target Name: MZT2A

NCBI ID: G653784

MZT2A

MZT2A: A Potential Drug Target and Biomarker

MZT2A, a protein encoded by the gene ZNF2, is a non-coding RNA molecule that has been shown to play a critical role in various cellular processes. MZT2A has a sequence similarity of 128 with the protein FBN1, which is a key regulator of blood clotting and a potential drug target in cancer. The discovery of MZT2A as a potential drug target has significant implications for the development of new treatments for various diseases.

MZT2A is a part of the ZNF2 gene family, which is known for its role in regulating gene expression and cell growth. The ZNF2 gene family is composed of several non-coding RNAs, including MZT2A, MZT2B, MZT3A, and MZT4A. These non-coding RNAs have been shown to play important roles in various cellular processes, including cell growth, apoptosis, and transcriptional regulation.

MZT2A is a 24.1 kilobase (kb) long RNA molecule with a unique structure that consists of a single exon and a single intron. The exon has a splice start site at position 6 and a splice endpoint at position 20, while the intron has a start site at position 18 and an endpoint at position 22. MZT2A has a calculated molecular weight of 13.9 kDa and a predicted pI of 5.95.

The MZT2A protein is highly conserved, with a calculated amino acid sequence of 235 amino acids. MZT2A has a distinct N-terminal region, which consists of a putative nuclear localization domain (NLD) and a transmembrane region (TM) that is similar to other ZNF2 proteins. The NLD is a region that is known to play a critical role in protein-protein interactions and has been shown to be involved in the regulation of cellular processes, including cell growth, apoptosis, and transcriptional regulation.

MZT2A has also been shown to have a significant role in cell migration and invasion. MZT2A has been shown to play a critical role in the regulation of the cell migration and invasion process, which is essential for the development of cancer. MZT2A has been shown to promote the migration and invasion of various cell types, including cancer cells.

In addition to its role in cell migration and invasion, MZT2A has also been shown to play a critical role in the regulation of cell apoptosis. MZT2A has been shown to regulate the apoptosis of various cell types, including cancer cells. MZT2A has been shown to induce apoptosis in a variety of cell types and to play a critical role in the regulation of cell cycle progression.

MZT2A has also been shown to have a significant impact on cellular processes that are important for the development and progression of cancer. MZT2A has been shown to promote the growth and survival of various cancer cell types and to play a critical role in the regulation of cell cycle progression.

The potential drug target status of MZT2A is supported by its expression in various tissues and its role in the regulation of cellular processes that are important for the development and progression of cancer. MZT2A has been shown to be expressed in a variety of tissues, including brain, spleen, and various cancer types.

In addition to its expression in various tissues, MZT2A has also been shown to play a critical role in the regulation of cellular processes that are important for

Protein Name: Mitotic Spindle Organizing Protein 2A

The "MZT2A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MZT2A comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets